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Mechanical Circulatory Support

PREFACE
Mechanical Circulatory Support

Brian O’Neill, MD, FACC
Editor

The utilization of mechanical circulatory support
(MCS) has increased in the United States over
the past 10 years. MCS initially primarily consisted
of the intra-aortic balloon pump and surgical implantation of extracorporeal membrane oxygenation, but there are now an ever-increasing
number of devices with unique characteristics in
terms of the amount of hemodynamic support
provided, as well as the option for isolated rightand left-sided support. Moving forward from the
need for surgical cutdowns for the implantation
of these large-bore devices, the routine use of
ultrasound-guided access with small-gauge micropuncture needles has facilitated the transformation of these procedures to a totally
percutaneous one. The field of structural heart disease has helped to usher in this era with the need
for reliable access and closure of large-bore access
to allow delivery of transcatheter aortic valve
replacement therapy.
As many patients have peripheral arterial disease, we continue to seek out new techniques to
allow perfusion to the leg during hemodynamic
support, and to be able to better manage vascular
complications when they may occur. In those patients who are eligible, the use of vascular closure
devices has allowed for the safe explant during the

same setting or on a different day when the device
is no longer required.
We have come to realize the importance of
MCS outside of those patients solely with cardiogenic shock. The fields of high-risk percutaneous
coronary intervention and structural heart disease
have benefited from the advances in MCS to allow
us to treat these higher-risk patients who may not
have been candidates for anything before. We
have also now gained more experience in
intermediate-term MCS for those patients who
may require a long-term durable ventricular assist
device or heart transplant. In this issue of Interventional Cardiology Clinics, we hope to touch on
each of these issues and offer a single source of information for those who have an interest in MCS.
On behalf of my coauthors, we hope you enjoy
the issue.
Brian O’Neill, MD, FACC
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